T

he Colombian government remains in the crosshairs of the pharmaceutical industry.

In comments filed with the US trade representative, the Pharmaceutical Research & Manufacturers of America argued that Colombia should be given added scrutiny for purportedly failing to sufficiently protect and enforce patent rights. The remarks from the trade group were submitted as the US Trade Rep prepares its priority watch list of countries that are singled out for practices deemed both favorable and unfavorable to American companies.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X